Tesaro PARP drug Niraparib/Zejula is selling well. This drug was discovered within Merck labs and practically given away to Tesaro for $7 million. Merck leaders then turn around and spend $1.6 billion to license a PARP compound from Astra Zeneca, Lynparza, and potentially a lot more in the future. You skipped or failed business class in school.
Zejula Niraparib
https://www.fool.com/investing/2016/07/03/a-big-breakthrough-for-ovarian-cancer-patients.aspx
Lynparza Olaparib
https://www.astrazeneca.com/media-c...trategic-oncology-collaboration-27072017.html
Zejula Niraparib
https://www.fool.com/investing/2016/07/03/a-big-breakthrough-for-ovarian-cancer-patients.aspx
Lynparza Olaparib
https://www.astrazeneca.com/media-c...trategic-oncology-collaboration-27072017.html